Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BioNTech SE Regulatory Filings 2020

Nov 10, 2020

30236_ffr_2020-11-10_dcc27779-b336-412c-94e9-1084be5fce30.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

6-K 1 bntx-6k_20201110.htm 6-K HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd" bntx-6k_20201110.DOCX.htm NG Converter v5.0.2.50

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF NOVEMBER 2020

COMMISSION FILE NUMBER 001-39081

BioNTech SE (Translation of registrant’s name into English)

An der Goldgrube 12

D-55131 Mainz

Germany

+49 6131-9084-0 (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7) : ☐

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

On November 10, 2020, BioNTech SE (the “Company”) issued a press release providing a development update and reporting its financial results for the three and nine months ended September 30, 2020, attached hereto as Exhibit 99.1.

The information contained in Exhibit 99.1 is furnished only and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, unless expressly set forth by specific reference in such a filing.

SIGNATURE

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioNTech SE
By: /s/ Dr. Sierk Poetting
Name: Dr. Sierk Poetting
Title: Chief Financial Officer

Date: November 10, 2020

EXHIBIT INDEX

Exhibit Description of Exhibit
99.1 Third Quarter 2020 Financial Results Press Release dated November 10, 2020.